Altace Lifecycle Management And Remoxy NDA Filing Top King’s Agenda
Executive Summary
King Pharmaceuticals's upcoming regulatory agenda includes near-term NDA filings for a co-formulation of the ACE inhibitor Altace and hydrochlorothiazide and the opioid Remoxy in conjunction with Pain Therapeutics